Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.
| Revenue (Most Recent Fiscal Year) | $1.20M |
| Net Income (Most Recent Fiscal Year) | $-22.70M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 20.49 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.16 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1844.49% |
| Net Margin (Trailing 12 Months) | -1844.49% |
| Return on Equity (Trailing 12 Months) | -202.41% |
| Return on Assets (Trailing 12 Months) | -140.67% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.88 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.88 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.05 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.25 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.19 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.29 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.13 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 31.15M |
| Free Float | 28.84M |
| Market Capitalization | $24.92M |
| Average Volume (Last 20 Days) | 0.42M |
| Beta (Past 60 Months) | -0.35 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.42% |
| Percentage Held By Institutions (Latest 13F Reports) | 10.01% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |